Optimal scheme of administration of pazopanib in thyroid carcinoma
Phase 1
- Conditions
- Iodine refractory Differentiated Thyroid CarcinomaMedDRA version: 14.1 Level: LLT Classification code 10043702 Term: Thyroid carcinoma System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2012-003162-41-FR
- Lead Sponsor
- Centre Léon Bérard
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 168
Inclusion Criteria
Informed consent signature
Differentiated thyroid carcinoma (DTC)
Resistance to therapeutique radioiodine
Disease progression
ECOG Performance Status = 0 or 1
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 84
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 84
Exclusion Criteria
Other histological type than DTC
Prior treatment with pazopanib
Prior malignancy
Active Central Nervous System metastasis
Risk for gastrointestinal bleeding
Poorly controlled hypertension
Active bleeding or bleeding diathesis
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method